ProductNum | picture | CAS No. | Name and description | Size | Formula | Quick order |
---|---|---|---|---|---|---|
GC31801-20mg |
|
107361-33-1 |
Enazadrem
|
0 | C18H25N3O | |
GC31801-10mg |
|
107361-33-1 |
Enazadrem
|
0 | C18H25N3O | |
GC31801-5mg |
|
107361-33-1 |
Enazadrem
|
0 | C18H25N3O | |
GC31801-1mg |
|
107361-33-1 |
Enazadrem
|
0 | C18H25N3O | |
GC31800-20mg |
|
607736-84-5 |
SUN 1334H
|
0 | C23H28Cl2F2N2O3 | |
GC31800-10mg |
|
607736-84-5 |
SUN 1334H
|
0 | C23H28Cl2F2N2O3 | |
GC31800-5mg |
|
607736-84-5 |
SUN 1334H
|
0 | C23H28Cl2F2N2O3 | |
GC31800-1mg |
|
607736-84-5 |
SUN 1334H
|
0 | C23H28Cl2F2N2O3 | |
GC31799-100mg |
|
844882-93-5 |
IFN alpha-IFNAR-IN-1 (IFN-alpha and IFNAR interaction inhibitor)
|
0 | C18H17NS | |
GC31799-50mg |
|
844882-93-5 |
IFN alpha-IFNAR-IN-1 (IFN-alpha and IFNAR interaction inhibitor)
|
0 | C18H17NS | |
GC31799-10mg |
|
844882-93-5 |
IFN alpha-IFNAR-IN-1 (IFN-alpha and IFNAR interaction inhibitor)
|
0 | C18H17NS | |
GC31799-5mg |
|
844882-93-5 |
IFN alpha-IFNAR-IN-1 (IFN-alpha and IFNAR interaction inhibitor)
|
0 | C18H17NS | |
GC31798-20mg |
|
796854-35-8 |
WAY-204688 (SIM-688)
|
0 | C34H31F3N2O2 | |
GC31798-10mg |
|
796854-35-8 |
WAY-204688 (SIM-688)
|
0 | C34H31F3N2O2 | |
GC31798-5mg |
|
796854-35-8 |
WAY-204688 (SIM-688)
|
0 | C34H31F3N2O2 | |
GC31798-1mg |
|
796854-35-8 |
WAY-204688 (SIM-688)
|
0 | C34H31F3N2O2 | |
GC31797-100mg |
|
3918-92-1 |
L-Valyl-L-phenylalanine (Valylphenylalanine)
|
0 | C14H20N2O3 | |
GC31797-50mg |
|
3918-92-1 |
L-Valyl-L-phenylalanine (Valylphenylalanine)
|
0 | C14H20N2O3 | |
GC31797-10mM(1mLinDMSO) |
|
3918-92-1 |
L-Valyl-L-phenylalanine (Valylphenylalanine)
|
0 | C14H20N2O3 | |
GC31796-20mg |
|
82989-25-1 |
Tazanolast (TO 188)
|
0 | C13H15N5O3 | |